The companies will initially focus on the development of companion diagnostics that can be used in research and clinical trials in collaborations with pharma companies.

Helio Diagnostics will help with feasibility and development, performance verification, analytical and clinical validation, industrialization and tech transfer, and more.

AD, the test measures epigenetic markers in mitochondrial DNA to assess the likelihood that a person with mild cognitive impairment will progress to dementia.

Last week, readers were most interested in a story about the lack of evidence to support the widespread use of multi-cancer screening tests.

Stakeholders noted that challenges like supply chain breakdowns and staffing shortages are too global in scope for any one ...

OGT will now offer Qiagen's Clinical Insight Interpret bioinformatics software along with its SureSeq next-generation sequencing panels.

The scientists said that the test could help clinicians overcome a lack of specificity in prostate-specific antigen tests and ...

Titled the RESULTS Act, the bill would use third-party private-payor data to set Medicare lab payment rates, addressing a ...

NEW YORK – Despite a sharp fall in BioAffinity Technologies' share price over the past year, its CEO said that the firm remains on solid footing, and it will continue its work to expand the reach of ...

PreCheck's laboratory infrastructure and operational expertise will be used to further validate and process NucleoBio's Prostac assay.

NEW YORK – Roche announced Thursday that the US Food and Drug Administration has categorized its Ionify 25-Hydroxy Vitamin D assay as "moderate complexity" under CLIA. The test runs on Roche's Cobas I ...

The company's clinical chemistry test uses the NGAL biomarker to determine a patient's risk of acute kidney injury.